MannKind Corporation
NASDAQ:MNKDBiotechnology
Healthcare
$3.95 -0.51%
-$0.02 today
- Market cap
- $1.27B
- Beta
- 1.11
- P/E (TTM)
- -50.3
- EPS (TTM)
- -$0.08
52W Low $2.23High $6.51
Volume 4.08M
Average 5.73M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$18.25M
FY 2025 · Annual
-57.1% YoYInvesting Cash Flow
-$304.80M
FY 2025 · Annual
Financing Cash Flow
$315.10M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (80.93M) | (87.4M) | (11.94M) | 27.59M | 5.86M |
| Depreciation & Amortization | 5.47M | 6.29M | 5.8M | 9.04M | 12.28M |
| Deferred Income Tax | 12.64M | 0 | 0 | 0 | (4.97M) |
| Stock-Based Compensation | 12.2M | 0 | 17.65M | 21.36M | 24.2M |
| Change in Working Capital | (17.73M) | (24.05M) | 14.63M | (36.47M) | (86.35M) |
| Accounts Receivables | (776K) | (11.81M) | 2.35M | 2.65M | (4.76M) |
| Inventory | (4.08M) | (5.67M) | 4.57M | (3.2M) | 10.4M |
| Accounts Payables | 1.37M | 4.1M | (1.47M) | (2.79M) | (16.71M) |
| Other Working Capital | (14.25M) | (10.67M) | 9.18M | (33.14M) | (75.27M) |
| Other Non-Cash Items | 6.63M | 24.47M | 7.96M | 21M | 67.23M |
| Operating Cash Flow | (61.71M) | (80.7M) | 34.09M | 42.51M | 18.26M |
| Capital Expenditures | (11.47M) | (7.59M) | (42.44M) | (9.69M) | (4.57M) |
| Acquisitions (Net) | (56.06M) | (15.34M) | 0 | 0 | (347.74M) |
| Purchases of Investments | (199.13M) | (5M) | (79.1M) | (273.79M) | (157.8M) |
| Sales of Investments | 59.06M | 0 | 119.17M | 58.13M | 221.72M |
| Other Investing Activities | 56.06M | 32.8M | 382K | 128.71M | (16.41M) |
| Investing Cash Flow | (151.54M) | 4.87M | (1.99M) | (96.65M) | (304.8M) |
| Debt Repayment | 281.08M | (1.09M) | (6.86M) | (133.17M) | 325M |
| Common Stock Issued | 1.89M | 22.56M | 6.89M | (6.09M) | 1.99M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (12.7M) | (62K) | 136.58M | 1.99M | (11.89M) |
| Financing Cash Flow | 270.27M | 21.41M | 136.61M | (137.27M) | 315.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 57.02M | (54.42M) | 168.71M | (191.4M) | 28.55M |
| Free Cash Flow | (73.18M) | (88.29M) | (8.35M) | 32.82M | 13.69M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$5.9M
+ D&A$12.3M
+ Stock-Based Comp$24.2M
- Deferred Tax-$5.0M
- Working Capital-$86.3M
+ Other Non-Cash$67.2M
= Operating Cash Flow$18.3M
- Capex-$4.6M
= Free Cash Flow$13.7M
Analysis
FY2025 free cash flow is $13.7M. FCF conversion is 233.5% of net income. Operating cash flow was $18.3M, with capex of -$4.6M. The largest bridge item is Working Capital at -$86.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 28, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 14, 2026 |
Does MNKD generate free cash flow?
MannKind Corporation (MNKD) generated $13.69M of free cash flow in fiscal 2025.
How much operating cash flow does MNKD produce?
Operating cash flow was $18.25M, before capital expenditures of $4.57M.
Continue the stock analysis
Jump to another research area for this company.